Icagen,'s Revenue in the fiscal year 2018 $ 13.58 millions
Icagen,'s Revenue in the fiscal year 2017 $ 22.66 millions
Icagen,'s Revenue in the fiscal year 2016 $ 12.00 millions
Icagen,'s Revenue in the fiscal year 2015 $ 1.59 millions
Icagen,'s Revenue in the fiscal year 2014 $ 0.54 millions
ICGND Revenue third quarter 2019 Y/Y Growth Comment
Icagen, Inc. reported Revenue increase of 19.58% year on year in the third quarter 2019, to $ 3.60 millions, this is lower than Icagen, Inc.'s recent average Revenue surge of 387.16%.
Looking into third quarter 2019 results within Medical Laboratories industry 13 other companies have achieved higher Revenue growth. While Icagen, Inc.' s Revenue growth of 19.58% ranks overall at the positon no. 884 in the third quarter 2019.
Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019
Icagen,'s Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
388.89 %
50.47 %
-81.09 %
(Sep 30 2015)
(Mar 31 2018)
ICGND's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2019 Icagen, Inc. disclosed drop in Revenue from the second quarter by -7.94% to $ 3.60 millions, from $ 3.91 millions achived in the previous reporting period.
But that's not important problem, as Icagen,'s Revenue generally seem to plunge in this quarter.
Within Medical Laboratories industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Icagen,'s Revenue growth quarter on quarter, overall rank is 3447.
In the III. Quarter 2019 Icagen, Inc. disclosed drop in Revenue from the second quarter by -7.94% to $ 3.60 millions, from $ 3.91 millions achived in the previous reporting period.
But that's not important problem, as Icagen,'s Revenue generally seem to plunge in this quarter.
Within Medical Laboratories industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Icagen,'s Revenue growth quarter on quarter, overall rank is 3447.
Icagen,'s 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Sep 30 2019)
12 Months Ending (Jun 30 2019)
12 Months Ending (Mar 31 2019)
12 Months Ending (Dec 31 2018)
12 Months Ending (Sep 30 2018)
Cumulative Revenue 12 Months Ending
$ 14.08
$ 13.49
$ 13.96
$ 13.58
$ 16.11
Y / Y Revenue Growth (TTM)
-12.55 %
-27.15 %
-29.9 %
-40.05 %
-28.88 %
Year on Year Revenue Growth Overall
Ranking
# 902
# 3498
# 0
# 3822
# 196
Seqeuential Revenue Change (TTM)
4.38 %
-3.37 %
2.79 %
-15.66 %
-13.04 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2996
# 735
# 0
# 3809
# 3157
Cumulative Revenue growth Comment
Icagen, showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2019. If the fiscal year would end in Sep 30 2019, Icagen,'s annual Revenue fall would be -12.55% year on year to $14 millions.
In the Healthcare sector 190 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 902, from total ranking in previous quarter at 3498.
Icagen, showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2019. If the fiscal year would end in Sep 30 2019, Icagen,'s annual Revenue drop would be -12.55% year on year to $14 millions.
In the Healthcare sector 190 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 902, from total ranking in previous quarter at 3498.
About Icagen, Revenue Growth Rates (ICGND), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
33.93%